Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - methylphenidatum hýdróklóríð - forðatafla - 36 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - methylphenidatum hýdróklóríð - forðatafla - 54 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - tafla - 10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 20 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 30 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 40 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 60 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

roche registration ltd. - ibandrónsýra - beinþynning, eftir tíðahvörf - lyf til að meðhöndla beinsjúkdóma - meðferð beinþynningar hjá konum eftir tíðahvörf við aukna hættu á beinbrotum. lækkun í hættu á hryggbrot hefur verið sýnt. verkun á lærlegg-háls beinbrot hefur ekki verið staðfest.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. sjá kafla 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.